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BACKGROUND. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene
that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently,
cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation of
inorganic pyrophosphate, a natural substrate of TNSALP and inhibitor of mineralization. Children
with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle weakness, and premature
deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected s.c.
to treat HPP. In 2012, we detailed the 1-year efficacy of asfotase alfa therapy for the life-threatening
perinatal and infantile forms of HPP.
METHODS. Here, we evaluated the efficacy and safety of asfotase alfa treatment administered to
children 6–12 years of age at baseline who were substantially impaired by HPP. Two radiographic
scales quantitated HPP skeletal disease, including comparisons to serial radiographs from similarly
affected historical control patients.
RESULTS. Twelve children receiving treatment were studied for 5 years. The 6-month primary
endpoint was met, showing significant radiographic improvement. Additional significant
improvements included patient growth, strength, motor function, agility, and quality of life,
which for most patients meant achieving normal values for age- and sex-matched peers that
were sustained at 5 years of treatment. For most, pain and disability resolved. Mild to moderate
injection-site reactions were common and were sometimes associated with lipohypertrophy. Low
anti–asfotase alfa antibody titers were noted in all patients. No evidence emerged for clinically
important ectopic calcification or treatment resistance.
CONCLUSIONS. Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy
with a good safety profile for children suffering from HPP.
TRIAL REGISTRATION. ClinicalTrials.gov NCT00952484 (https://clinicaltrials.gov/ct2/show/
NCT00952484) and NCT01203826 (https://clinicaltrials.gov/ct2/show/NCT01203826).
FUNDING. Alexion Pharmaceuticals Inc. and Shriners Hospitals for Children.

Introduction
Hypophosphatasia is the inborn error of metabolism caused by loss-of-function mutation(s) of the gene
that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP) (1, 2). TNSALP is a cellsurface phosphohydrolase richly expressed in bone, liver, and kidney (3), and deficient TNSALP activity in
hypophosphatasia leads to extracellular accumulation of its natural substrates, including inorganic pyrophosphate (PPi) (4) and pyridoxal 5′-phosphate (PLP) (5). PPi is a potent inhibitor of mineralization (6),
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Figure 1. Study design and patient participation. During the 6-month initial phase involving 13 participants, 1 child withdrew for elective surgery after
1 month of treatment. The remaining 12 were assessed up to 5 years (60 months) of treatment and continue on study. Data were pooled across these 2
phases for analysis. The radiographic findings were contrasted to 2-year experience with 16 historical control patients. *ClinicalTrials.gov: NCT00952484,
NCT01203826. LOCF, last observation carried forward.

and the excessive PPi in hypophosphatasia can block hydroxyapatite crystal formation within the skeletal
matrix (7, 8), causing rickets during growth (9) or osteomalacia in adult life (10). Impaired hydrolysis of
PLP in severely affected babies can lead to neurotransmitter deficiency and vitamin B6–dependent seizures
(11). The clinical expressivity of hypophosphatasia is classified according to whether there are dental complications alone (odontohypophosphatasia) or to patient age when skeletal and other problems first manifest (1, 2, 12). Perinatal hypophosphatasia is almost always fatal soon after birth (13), and infantile hypophosphatasia has a mortality estimate of 50% during the first year of life (1, 2). Childhood hypophosphatasia
features rickets often complicated by skeletal pain, fracturing, muscle weakness, abnormal ambulation or
gait, and premature loss of deciduous teeth (1, 2, 14).
Asfotase alfa is a recombinant, bone-targeted, human TNSALP developed to treat hypophosphatasia
(15). In 2012, we reported that infants and young children (≤3 years of age) with life-threatening perinatal
and infantile hypophosphatasia showed substantial radiographic healing of rickets, improved respiratory
status, and better physical function during 1 year of asfotase alfa treatment (9). Here, we assess the impact
of 5 years of asfotase alfa treatment in a separate cohort of older children (6–12 years of age) with either
infantile- or childhood-onset disease who were substantially impaired by hypophosphatasia, including
effects on their skeletal manifestations, growth, physical function, and quality of life.

Results
Patient Characteristics. Thirteen children — 11 boys and 2 girls with infantile hypophosphatasia or compromised by childhood hypophosphatasia (16) — were enrolled between September 2009 and January 2010
for treatment (Figure 1). Their case summaries are detailed in the Supplement; supplemental material available online with this article; doi:10.1172/jci.insight.85971DS1. Enrollment ages ranged from 6–12 years
(Table 1). Reported skeletal abnormalities included knock knees (77%), rachitic chest (46%), bowing of
leg(s) (39%), and craniosynostosis (31%) and were accompanied by muscle weakness in most patients and
an unusual gait in all. Bone pain often limited activities (46%) and/or required analgesics (39%). Nearly
half the patients had poor weight gain and prior difficulty feeding. Hypercalcemia had occurred in 31%.
After 1 month of treatment, 1 boy withdrew for elective scoliosis surgery. Figure 2 is an example of the
radiographic abnormalities that can be observed in a child with untreated hypophosphatasia.
The 16 historical controls — 11 boys and 5 girls with infantile or childhood hypophosphatasia —
insight.jci.org   doi:10.1172/jci.insight.85971
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Table 1. Patient demographic and baseline characteristics
Historical Control Patients

Treated Patients

16

13

Mean ± SD
Median (min, max)

6.0 ± 1.8
5.5 (4, 11)

8.8 ± 2.2
8.6 (6, 12)

Male

69% (11)

85% (11)

Not Hispanic or Latino

NA

92% (12)

NA

92% (12)

44% (7)
56% (9)

38% (5)
62% (8)

7.4 ± 9.5
6.0 (0, 40)

10.5 ± 7.0
12.0 (1, 22)

1.44 ± 0.96
1.0 (0.0, 3.5)

2.77 ± 1.33
3.0 (0.5, 6.0)

NA

5.01 ± 0.97
4.86 (3.74, 6.96 [0.75–5.71 µM])

323 ± 178
328 (85, 726 [5.7–61.2 ng/ml])

214 ± 127
218 (76, 527 [5.7–61.2 ng/ml])

2.5 ± 0.10
2.52 (2.35, 2.78 [2.12–2.57 mmol/l])

2.5 ± 0.10
2.50 (2.37, 2.67 [2.12–2.57 mmol/l])

NA

100% (13)
100% (13)
85% (11)
77% (10)
62% (8)
54% (7)
46% (6)
46% (6)
46% (6)
46% (6)
46% (6)
46% (6)
46% (6)
39% (5)
39% (5)

n
Age (yrs) at enrollment

Sex, % (n)
Ethnicity, % (n)
Race, % (n)
White
Form of hypophosphatasia, % (n)
Infantile
Childhood (≥6 mos to <18 yrs)
Age (mos) at onset of hypophosphatasia symptoms
Mean ± SD
Median (min, max)
Baseline RSS (0 = normal, 10 = severe)
Mean ± SD
Median (min, max)
Baseline plasma PPi (μM)
Mean ± SD
Median (min, max [normal range])
Baseline serum PLP (ng/ml)
Mean ± SD
Median (min, max [normal range])
Baseline serum calcium (mmol/l)
Mean ± SD
Median (min, max [normal range])
Hypophosphatasia-related disease history, % (n)
Unusual gait or running
Premature tooth loss
Delayed (≥15 mos) walking
Knock knees
Muscle weakness
Elevated serum phosphorous
Difficulty eating/swallowing
Difficulty gaining weight
Hypermobility
Joint pain
Muscle pain
Abnormally shaped chest
Bone pain severe enough to limit activities
Bone pain severe enough to require medication
Bowing of legs

NA, not available; PLP, pyridoxal-5′ phosphate; PPi, inorganic pyrophosphate; RSS, Rickets Severity Score.

were slightly younger compared with the treatment group when their first study-eligible radiographs
had been taken, and they had a lower median serum ALP level than the treatment group. All other
assessed characteristics, including their medical histories and demographic findings, were similar to the
treatment group (Table 1).
Primary endpoint: skeletal radiographic changes. After 6 weeks of asfotase alfa administered s.c., the median Radiographic Global Impression of Change (RGI-C) score (see Methods) had improved significantly
(+1.0 [0.0, +2.0; min, max]; P = 0.001). Except where noted, values are expressed as median (min, max).
insight.jci.org   doi:10.1172/jci.insight.85971
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Figure 2. Skeletal features of untreated hypophosphatasia.
Untreated, the radiographic features of hypophosphatasia
in children (e.g., patient 7) include, as in the wrist pictured,
osteopenia, metaphyseal fraying, metaphyseal flaring,
and metadiaphyseal sclerosis, and as in the knee pictured,
characteristic “tongues” of radiolucency, irregularity of
the provisional zone of calcification, distal metaphyseal
demineralization, transverse subphyseal band of lucency,
and apparent physeal widening.

Further improvement occurred by 6 months (Figure 3)
and persisted through 5 years (+2.2 [+1.7, +2.7];
P = 0.0005) (see Supplement). For no patient did
the score worsen. However, at 5 years of treatment,
the median score had not reached +3 for complete
or nearly complete healing of all treated patients. In
contrast, no significant change occurred in the RGI-C
score of the historical controls spanning up to 2 years
(Figure 3). The RGI-C responder analysis showed
69% (9/13) of treated patients achieved “responder” designation (RGI-C score ≥ +2) at 6 months of
therapy (last observation carried forward [LOCF]
data imputation applied) compared with 6% (1/16)
of the historical controls (P = 0.007). The percentage
of treated patients considered responders then further
improved steadily; 75% at 2 years, 88% at 3 years, and
92% at 5 years (1 patient had withdrawn at month 1).
Representative radiographs are illustrated in Figure
4. Consistent with the RGI-C findings, the Rickets
Severity Score (RSS; see Methods) analysis confirmed
improvement of rickets with treatment (documenting
significantly decreased median RSS scores comparing
the first eligible radiographs with all subsequent evaluated time points) as contrasted to the historical controls (Supplemental Table 1).
TNSALP replacement and substrates. Twelve of the 13 treated patients had at least 1 mutant TNSALP allele
identified using PCR and DNA sequencing of all coding exons and splice sites (Supplemental Table 2).
The exception (patient 11) has not shown a TNSALP gene mutation despite extensive molecular investigations. The median serum ALP activity of the treatment group at baseline was 49 IU/l (min, max: 27,
68; see Supplement for age- and sex-specific normal ranges for each patient) and then rapidly increased,
presumably reflecting asfotase alfa activity, with treatment. At 5 years of therapy, it remained markedly elevated at 5747 IU/l (3,039, 9,959). Baseline plasma PPi median concentration, 4.9 μM (3.7, 7.0), was near
the upper limit of the age-dependent reference range (0.75–5.71 μM). Baseline plasma PLP median concentration, 218 ng/ml (76, 527), was clearly elevated (normal 5.7–61.2 ng/ml). At 6 weeks of treatment, rapid
and significant reduction of plasma PPi and PLP concentrations had achieved the normal limits for most
treated patients (2.0 μM [1.3, 3.1] and 10.6 ng/ml [0.9, 40.3], respectively). Then, normal levels generally
persisted throughout the study (Supplemental Figure 1).
Growth. With treatment, the first significant increase in the group’s weight Z scores (Figure 5A) was
identified at 6 weeks (baseline: –1.21 [–8.2, 2.3]; 6 weeks: –0.92 [–8.0, 2.1], P = 0.0048), and the first significant increase in the group’s height Z scores was noted after 1.5 years (baseline: –1.26 [–6.6, 0.0]; 1.5 years:
–0.87 [–6.6, –0.3], P = 0.0257) (Figure 5B). BMI was increased at 5 years of treatment (baseline: –0.57
[–1.4, 2.4]; 5 years: 0.05 [–1.0, 2.2], P = 0.0077) (Figure 5C).
Strength. Most treated patients became stronger for their age and sex; e.g., right hip abduction baseline median at 13.6 lbs was 7.3 and 22.1 (min, max, respectively; 50% predicted for healthy peers). At 6
months, 18.3 lbs, minimum and maximum values were 8.4 and 28.2, respectively (P = 0.0018 or 60% predicted). At 5 years, 30.7 lbs, minimum and maximum values were 19.5 and 84.4, respectively (P = 0.0079
insight.jci.org   doi:10.1172/jci.insight.85971
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Figure 3. Skeletal improvements during treatment with asfotase alfa. Changes in RGI-C scores during 6 months and
2 years of treatment with asfotase alfa. Individual dots illustrate the distribution of individual patient scores at each
time point. Boxes represent the median RGI-C scores and represent first and third quartiles. Whisker lines above and
below the boxes represent the end-range of patient scores. The RGI-C is scored on a scale ranging from –3 to +3, with
0 representing no change. Negative values represent worsening, and positive values represent improvement or healing. A score of +3 indicates nearly complete or complete healing. Median RGI-C scores for the historical controls and
asfotase alfa were 0 and 2, respectively, at 6 months and 2 years. The number of patients assessed at each time point
is shown below each bar. P ≤ 0.0001 by Wilcoxon signed-rank test at all time points compared with no change.

or 91% predicted). Significant improvements were similarly documented for hip and knee extensors and
knee flexors (Supplemental Figure 2).
Physical function. Before treatment, gross motor delays and functional disability were documented in
most patients; e.g., 9 of the 13 had a subnormal (<80% predicted) 6-minute walk test (6MWT). After 5
years of treatment, 7 of these 9 children achieved or surpassed 80% of the predicted distance (± 2 SD
mean), indicating normal ambulation. The median score increased from 61% at baseline to 83% at 5 years
(P = 0.0002; Figure 6A; Video 1; Supplemental Figure 3).
The median value for the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)
Strength and Agility Composite Score at baseline (28.0 [20.0, 37.0]; percentile rank = 1.0) was greater than
2 SD below the median score of 50 for healthy, age-matched peers (17). During treatment, it improved,
reaching the normal range after 1 year, and was significantly better after 5 years (46.0 [33.0, 64.0]; P ≤
0.0001; percentile rank = 35.0) (Figure 6B; Video 2; Supplemental Figure 4). The magnitude of change in
the standard scores indicated gross motor function within the normal range (± 1 SD mean).
Pain and disability assessments. Improvements in the above effort-dependent functional tests were substantiated by the parent-reported Child Health Assessment Questionnaire (CHAQ) and Pediatric Outcomes
Data Collection Instrument (PODCI) results. These clinically meaningful advances persisted through 5
years. The elevated CHAQ pain (20.0 [0.0, 72.0]) and disability (1.0 [0.0, 2.3]) medians at baseline were 0
at 5 years of treatment, indicating no pain or disability for most patients (0.0 [0.0, 60.0], P = 0.1125; 0.0
[0.0, 1.0], P = 0.0002, respectively) (Figure 6C). The PODCI global function median score, which was
abnormal at baseline (27.0 [–2.0, 55.0]), improved to slightly above normal at the 5-year assessment (52.0
[28.0, 57.0], P = 0.0002).
Safety. There were no deaths, serious adverse events (AEs), or withdrawals due to AEs. One patient
receiving asfotase alfa 9 mg/kg/week s.c. underwent dose reduction for a low plasma PLP level. Four
patients had injection-associated reactions (IARs) (10 events) during the first month of treatment. All were
insight.jci.org   doi:10.1172/jci.insight.85971
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Figure 4. Representative radiographic changes. Radiographic changes were documented in 12 treated patients and are illustrated in the Supplemental
Methods. Patient 7, a 6-year-old boy at enrollment, is shown. RGI-C, Radiographic Global Impression of Change; RSS, Rickets Severity Score. Note the
improvements at 6 months of treatment that persist after 5 years of therapy.

injection-site reactions (ISRs), with the exception of nausea and peripheral edema in 1 patient, and all
were assessed by the investigators as mild. Each patient experienced at least 1 treatment-emergent AE; 86%
mild and 14% moderate in severity. Most AEs (53%) were considered by the investigators to be unrelated
to the treatment. When we excluded the ISRs, 2% of AEs were deemed treatment related. The most common therapy-related AEs were ISRs that were typically mild (Table 2 and Supplemental Figure 5A). For 8
patients, 26 events were considered focal lipohypertrophy, of which 8 were moderate in severity (Supplemental Figure 5B); the others were mild at data cutoff, and no dose adjustments were made. The lipohypertrophy occurred for 6 patients receiving 6 injections weekly and 2 patients receiving 3 injections weekly, all
receiving the same weekly dose (mg/kg) of asfotase alfa. At 3 years of treatment and thereafter, localized
lipohypertrophy persisted in 6 of the 8 patients. The dose of asfotase alfa was reduced for 1 patient with
mild ISRs (multiple macules). To minimize ISRs, injection-site rotation was emphasized for all patients.
Surveillance of the patients’ radiographs showed no evidence of ectopic calcification. On ophthalmoscopy,
the retinal examinations were consistently unremarkable. However, 46% (6 of 13) of the patients showed small
refractile deposits in the conjunctiva or cornea presumed to contain calcium. For 5 patients, these were considered possibly or probably related to the treatment. No deposit was deemed clinically apparent or significant.
No patient developed nephrocalcinosis, although after approximately 2 years of treatment, renal sonography
revealed “focal echogenicity” consistent with a small renal stone present for 6 months in 1 kidney of 1 patient.
All 12 patients tested would show anti–asfotase alfa antibodies. Five of the 6 patients who began treatment in the 3 mg/kg dose group were antibody positive by Week 6, and all were antibody positive at Week
12 of treatment. In those starting in the 2 mg/kg dose group, 1 patient was antibody positive by Week 6,
and 5 patients were positive by Week 48. In 5 of the 12 patients, the antibodies were neutralizing in vitro at
1 or more time points, but with no apparent compromise of therapeutic efficacy.
insight.jci.org   doi:10.1172/jci.insight.85971
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Table 2. Injection-site reactions
System Organ Class Preferred Term

Total
Erythema
Hypertrophy
Pruritus
Pain
Atrophy
Discoloration
Swelling
Induration
Nodule
Papule
Urticaria

Events

250
71
26
23
18
13
17
12
1
1
1
1

Asfotase Alfa (n = 13)
Patients, n (%)

12 (92)
11 (85)
8 (62)
7 (54)
6 (46)
5 (38)
5 (38)
3 (23)
1 (8)
1 (8)
1 (8)
1 (8)

Discussion
Hypophosphatasia features the greatest range of severity of all skeletal diseases (1) and represents the last
rickets or osteomalacia to have a medical treatment (2, 18). Asfotase alfa is a first-in-class, bone-targeted,
enzyme replacement therapy for hypophosphatasia (2).
In this study, asfotase alfa was administered for the first time to older children (6–12 years old) impaired
by the infantile and childhood forms of hypophosphatasia, all of whom had skeletal involvement, muscle
weakness, and/or difficulties with ambulation. Due to the rarity of hypophosphatasia (1), a concurrent
control group was not possible, but evaluation of the primary outcome objective (12) concerning the radiographic changes of this disorder was improved using radiographs from a pediatric historical control group,
also with infantile or childhood hypophosphatasia, assessed concomitantly by the same radiologists.
Skeletal improvement with asfotase alfa therapy was verified using 2 scales to study (9) the sequential
radiographs of the 12 treated patients and the 16 age- and sex-matched historical control patients. Both
scales documented no change in the controls but instead documented substantial healing of the skeletal
disease after 6 months of treatment that persisted through the 5 years of therapy. Skeletal healing did not
become complete for all patients.
As the weakness improved and the skeleton mended, there was substantially better physical function,
including walking distance, and most patients showed improved growth. Gross motor function, strength for
all proximal muscles tested, agility, and stamina typically achieved their normal ranges and together were
the basis for independent and age-appropriate performance of daily living activities. For most patients, their
pain and disability resolved. Consistent with the radiographic findings, the treated patients demonstrated
better skeletal mineralization assessed as bone mineral density quantitated by dual-energy x-ray absorptiometry and histomorphometry of transiliac crest bone biopsies (data not shown). Low titers of anti–asfotase alfa antibodies were found in all patients tested, but there was no evidence of resistance to this biologic.
Although the pathogenesis of the muscle weakness of hypophosphatasia is not understood (1, 2),
it can be an important complication. Notably, the muscle weakness, hyperphosphatemia, and rickets
or osteomalacia characteristic of hypophosphatasia (1, 2) are hallmarks of toxicity from the first-generation bisphosphonate, etidronate, a synthetic analog of PPi (19). Perhaps the high extracellular levels of PPi in hypophosphatasia somehow compromise muscle function and are corrected by asfotase
alfa treatment.
No deaths or safety-related discontinuation of therapy occurred during this study. Asfotase alfa treatment was generally well tolerated and safe. Although it markedly increased circulating ALP activity, no
clinically important ectopic mineralization occurred. Possibly, avoidance of ectopic calcification in our
treated patients reflected reduction of extracellular PPi levels into the normal range but not overcorrection
(i.e., suppression) (19). The most common AEs were mild to moderate ISRs. Lipohypertrophy appeared in
some children, but its pathogenesis is unknown.
insight.jci.org   doi:10.1172/jci.insight.85971
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Figure 5. Growth during treatment with
asfotase alfa. Growth was assessed by Z
scores for (A) weight, (B) height, and (C)
BMI. For all graphs, individual dots indicate
individual patient scores at each time
point. Median, min, max, and n values are
given below each panel. P values at 5 years
from Wilcoxon signed-rank test.

In conclusion, asfotase alfa treatment has substantial efficacy for children impaired by hypophosphatasia.
Better stature and improved strength
and agility accompanied significant
healing of the skeletal manifestations
and persisted through 5 years of treatment. The treatment was well tolerated
and seemed safe, with a favorable benefit-risk profile. In 2015, asfotase alfa
became the only approved medical
therapy for hypophosphatasia in Japan
and the only approved medical therapy
for pediatric-onset hypophosphatasia
in Canada, the European Union, and
the United States.

Methods
Study design. This open-label study
(NCT00952484 and NCT01203826)
sponsored by Alexion Pharmaceuticals Inc. evaluated the efficacy, safety,
tolerability, and pharmacokinetics of
asfotase alfa given to children compromised by hypophosphatasia. The
study began as a 6-month assessment
of 6- to 12-year-old, Tanner stage
≤2 survivors of infantile hypophosphatasia or patients with childhood
hypophosphatasia (16). Those who
completed this initial study entered an
extension phase (Figure 1). Our report
summarizes the findings during their
first 5 years of treatment. The data
cutoff was November 5, 2014; the
study is ongoing.
Inclusion criteria required radiographic skeletal features of hypophosphatasia-related rickets, serum ALP
activity below age-adjusted lower limits of normal, and plasma PLP levels
at least twice the upper limit of normal. Serum 25-hydroxyvitamin D had
to be greater than or equal to 20 ng/ml
(50 nM). Exclusion criteria included
treatable rickets, hypocalcemia, hypoinsight.jci.org   doi:10.1172/jci.insight.85971
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Figure 6. Functional assessment during
treatment with asfotase alfa. (A) Percent
predicted 6MWT distance median achieves
the normal range after 6 months of
treatment and is sustained at 5 years of
therapy. P ≤ 0.0005 by paired t test for the
mean difference between each time point
and baseline. (B) Gross motor function,
assessed using the BOT-2 Running Speed
and Agility subtest (17), shows median
scores reaching the normal range (gray
area) by 1 year of treatment that were
sustained. Median, min, max, and n values
are given within the figure. (C) Disability
assessment using the CHAQ (24) shows
patient improvement. *P ≤ 0.05, **P ≤
0.01, ***P ≤ 0.001 mean difference for
each time point compared with baseline
by paired t test. Median, min, max, and n
values are given below each figure. For all
graphs, individual dots indicate individual
patient scores at each time point. Gray
area represents the normal range.

phosphatemia, or bisphosphonate
exposure (see Supplemental Methods). Radiographic skeletal changes
during the first 2 years of asfotase alfa
treatment were compared with similar but untreated pediatric historical
controls with hypophosphatasia who
had been studied at Shriners Hospital
for Children but were too old for the
treatment study or declined participation. Their bilateral wrist and/or knee
radiographs, previously obtained at
intervals spanning 6 months to 2 years
between 5 and 12 years of age, were
evaluated as close to 6 months or 1–2
years apart for comparison with the
treatment group.
Asfotase alfa was provided by
the sponsor, Alexion Pharmaceuticals Inc. Patients to receive s.c.
injections of asfotase alfa (40 or 100
mg/ml concentration) were initially
randomized to 2 or 3 mg/kg thrice
weekly (i.e., 6 or 9 mg/kg/week) for
6 months (Figure 1). In the extension study, patients initially received
3 mg/kg/week either as 0.5 mg/kg 6
times weekly or 1 mg/kg thrice weekly until preliminary analysis led to a
protocol amendment that doubled
the dose to 6 mg/kg/week to maintain therapeutic efficacy. Doses could be adjusted by the investigator
together with the sponsor for safety concerns (any time) or lack of efficacy (extension phase only). Since
a separately identified historical control patient group was used for comparison, there was no randomization between the drug-treated and control patients.
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Outcome assessments. The primary endpoint objective, evaluation of changes in the skeletal manifestations of hypophosphatasia (see Supplemental Methods), was obtained using the RGI-C (9) and RSS (20).
The RGI-C, a 7-point ordinal scale, assesses hypophosphatasia skeletal disease in wrists and knees, including physeal widening, irregularity of the provisional zone of calcification, metaphyseal flaring, radiolucencies, and patchy osteosclerosis, as well as recent fractures (see Supplemental Methods) (9). The changes
compared with baseline were quantified independently by 3 pediatric radiologists blinded to treatment time
points and group assignments. For the RGI-C, +3 signifies complete or nearly complete healing, whereas
–3 represents severe worsening. The scores per patient were averaged across radiologists at each time point.
An RGI-C “responder” had a score greater than or equal to +2 (i.e., substantial or near/complete healing)
(9). The RSS, which was developed to assess nutritional rickets, was scored by the same individual rater to:
(i) evaluate the treated patients’ radiographs throughout the study and (ii) evaluate the historical control
radiographs representing 6-month, 1-year, and 2-year intervals. Knee and wrist growth-plate abnormalities
and metaphyseal fraying and cupping were rated according to a 10-point scale (0 = no rickets; 10 = severe
rickets), with scores for each radiograph determined in random order (Supplemental Table 3) (20).
Secondary endpoint assessments included changes in TNSALP substrate levels (i.e., plasma PPi and
PLP); growth (i.e., height, weight, and BMI Z scores); strength of muscle groups that move the hips and
knees, measured using a hand-held dynamometer (21); walking ability and endurance/speed, using a
6MWT (22); physical function and strength by BOT-2 (17); global function, including pain and interference
with normal activities, by the PODCI (23); and disability by the CHAQ (24) (Supplemental Methods). Normative PODCI scores for a healthy population have a mean of 50 with standard deviation of 10 and range
from –77 (worst) to +58 (best). The CHAQ disability scores range from 0–3, with higher scores indicating
greater disability.
Safety and tolerability primary endpoint surveillance included evaluation of AEs, deaths, vital signs,
physical examination, laboratory testing (standard biochemistry, hematology, and urinalysis; Covance
Inc.), ophthalmologic examination for ectopic calcification (during the extension phase), renal ultrasound
for nephrocalcinosis, and anti–asfotase alfa antibody formation.
Statistics. Data management and statistical analyses (SAS Version 9.2, SAS Institute Inc.) were performed by the sponsor. Except where noted, values are expressed as median (min, max). The RGI-C
median scores were compared using Wilcoxon rank-sum test. Missing values were imputed with LOCF,
and patients with no postbaseline assessment were assigned “no change” (e.g., RGI-C = 0). Observed
median and mean within-group changes were also assessed for difference from 0 using the Wilcoxon
signed-rank test and paired t test. All analyses were 2-sided, with significance defined as P less than 0.05.
Otherwise, descriptive statistics are reported.
Study approval. Safety and efficacy surveillance included an independent monitoring board. The study
was designed by the authors and sponsor. The protocol, its amendments, and informed consent/assent documents were approved by the governing IRBs for Shriners Hospital for Children and for the University of
Manitoba. Written informed consent was obtained from the parent(s) or legal guardian(s) and assent from
the study patients. All authors affirm data completeness and accuracy and protocol adherence.
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